Oncotarget

Case Reports:

This article has an addendum. Addendum in: Oncotarget. 2022; 13:983-983.

A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial

Guillermo de Velasco _, Lucia Carril-Ajuria, Felix Guerrero-Ramos, Teresa Alonso-Gordoa, Juan F. Rodríguez-Moreno, Alberto Carretero, Maricruz Martin-Soberon, Federico de la Rosa-Kehrmann and Daniel Castellano

PDF  |  Full Text  |  How to cite

Oncotarget. 2020; 11:4457-4462. https://doi.org/10.18632/oncotarget.27807

Metrics: PDF 953 views  |   Full Text 1817 views  |   ?  


Abstract

Guillermo de Velasco1, Lucia Carril-Ajuria1, Felix Guerrero-Ramos2, Teresa Alonso-Gordoa3, Juan F. Rodríguez-Moreno4, Alberto Carretero1, Maricruz Martin-Soberon1, Federico de la Rosa-Kehrmann2 and Daniel Castellano1

1 Medical Oncology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain

2 Urology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain

3 Medical Oncology Department, Hospital Universitario Ramón y Cajal, Comunidad de Madrid, Madrid, Spain

4 Medical Oncology Department, Hospital Universitario HM Sanchinarro, Comunidad de Madrid, Madrid, Spain

Correspondence to:

Guillermo de Velasco,email: [email protected]

Keywords: kidney cancer; renal cell carcinoma; neoadjuvant treatment; cabozantinib; trial

Received: September 18, 2020     Accepted: October 27, 2020     Published: November 24, 2020

Copyright: © 2020 de Velasco et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it should be avoided in most poor-risk patients. Nevertheless, it should still be considered in patients responding to systemic therapy and good-risk patients not requiring systemic treatment.

This case series of the phase 2 CABOPRE trial suggests neoadjuvant cabozantinib may be able to induce rapid and significant responses in some intermediate-risk advanced renal cell carcinoma patients facilitating resectability.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27807